At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 132 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Abemaciclib for Metastatic Breast Cancer. Completed, enrolled 132 participants across 36 sites in 4 countries.
Detailed Summary
The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesBelgium, France, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionApr 2016
Study CompletionOct 2018
TodayJul 2026
First PostedApr 3, 2014
Enrollment StartJun 10, 2014
Primary CompletionApr 30, 2016
Study CompletionOct 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.2 years ago
Interventions
Abemaciclibdrug
Administered orally